Cargando…

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

BACKGROUND: There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical costs among US patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergman, Martin J., Zueger, Patrick, Patel, Jayeshkumar, Saffore, Christopher D., Topuria, Ia, Cavanaugh, Cristi, Fang, Siran, Clewell, Jerry, Ogdie, Alexis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931970/ https://www.ncbi.nlm.nih.gov/pubmed/36333490 http://dx.doi.org/10.1007/s40744-022-00504-2

Ejemplares similares

Racial Differences in Prevalence and Treatment for Psoriatic Arthritis and Ankylosing Spondylitis by Insurance Coverage in the USA
por: Ogdie, Alexis, et al.
Publicado: (2021)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis
por: Walsh, Jessica A., et al.
Publicado: (2023)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
por: Michelena, Xabier, et al.
Publicado: (2022)

Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
por: Ogdie, Alexis, et al.
Publicado: (2022)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Correction: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
por: Ogdie, Alexis, et al.
Publicado: (2022)

Real-World Patient Experience on the Path to Diagnosis of Ankylosing Spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2019)

Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry
por: Sørensen, Jan, et al.
Publicado: (2015)

Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
por: Deodhar, Atul, et al.
Publicado: (2021)

Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy
por: Kim, Hyoun-Ah, et al.
Publicado: (2022)

Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2022)

Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
por: Nielsen, Christel, et al.
Publicado: (2017)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis
por: Bonek, Krzysztof, et al.
Publicado: (2022)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2014)

Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis
por: Aboud, Fatma Mohammed, et al.
Publicado: (2023)

Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis
por: Bergman, Martin, et al.
Publicado: (2018)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Obesity and Psoriatic Arthritis: A Narrative Review
por: Kumthekar, Anand, et al.
Publicado: (2020)

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015)

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Deyab, Gia, et al.
Publicado: (2017)

Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis
por: Brock, C., et al.
Publicado: (2021)

Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
por: Girbash, Ehab F., et al.
Publicado: (2023)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study
por: Lindström, Ulf, et al.
Publicado: (2016)

Psoriatic arthritis: prospects for the future
por: Hackett, Simon, et al.
Publicado: (2022)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
por: Smolen, Josef S, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nu35odsqsac9vi2h9e8a28ujug